Видео ютуба по тегу Medicines: Imetelstat

Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits
Favorable Overall Survival with Imetelstat Treatment Correlates with Other Clinical Benefits
Imetelstat: Understanding how this drug fights Myelodysplastic Syndrome (MDS) │ Pharmacology
Imetelstat: Understanding how this drug fights Myelodysplastic Syndrome (MDS) │ Pharmacology
Dr. Tefferi on the Toxicity Profile of Imetelstat
Dr. Tefferi on the Toxicity Profile of Imetelstat
Imetelstat shows promise in advanced myelofibrosis
Imetelstat shows promise in advanced myelofibrosis
Telomerase Targeting Drug Demonstrates Benefit in Myelofibrosis Treatment
Telomerase Targeting Drug Demonstrates Benefit in Myelofibrosis Treatment
The safety profile of imetelstat in myeloid malignancies
The safety profile of imetelstat in myeloid malignancies
Imetelstat in high-risk triple-negative myelofibrosis
Imetelstat in high-risk triple-negative myelofibrosis
What do phase II data show about the safety of imetelstat in R/R MF?
What do phase II data show about the safety of imetelstat in R/R MF?
hTERT reduction by imetelstat correlates with clinical activity in MDS
hTERT reduction by imetelstat correlates with clinical activity in MDS
IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS
IMerge update: continuous transfusion independence & disease modification with imetelstat in LR-MDS
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Prolonged & continuous transfusion independence after imetelstat treatment in the IMerge trial
Фаза 3 исследования IMerge: Долгосрочные результаты применения иметелстата у пациентов с низким р...
Фаза 3 исследования IMerge: Долгосрочные результаты применения иметелстата у пациентов с низким р...
IMPROVE-MF: imetelstat and ruxolitinib in patients with myelofibrosis
IMPROVE-MF: imetelstat and ruxolitinib in patients with myelofibrosis
How leukaemia drug imetelstat causes cell death
How leukaemia drug imetelstat causes cell death
Imetelstat for LR-MDS: insights from the IMerge trial
Imetelstat for LR-MDS: insights from the IMerge trial
Imetelstat for transfusion-dependent R/R MDS
Imetelstat for transfusion-dependent R/R MDS
Phase III trial of imetelstat versus best available therapy in refractory MF
Phase III trial of imetelstat versus best available therapy in refractory MF
Telomerase inhibitor Imetelstat
Telomerase inhibitor Imetelstat
Imetelstat efficacy is independent of molecular subtypes in R/R LR-MDS
Imetelstat efficacy is independent of molecular subtypes in R/R LR-MDS
Imetelstat in heavily-transfused lower-risk R/R MDS
Imetelstat in heavily-transfused lower-risk R/R MDS